<DOC>
	<DOC>NCT01967199</DOC>
	<brief_summary>The purpose of this study is to establish the safety and effectiveness of paclitaxel eluting balloon (SeQuent Please) compared to coronary stenting with the Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine) in the treatment of drug eluting stent restenosis.</brief_summary>
	<brief_title>Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis</brief_title>
	<detailed_description />
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient must be more than or equal to 20 years of age Restenosis after drugeluting stents (&gt;50% by visual estimate) Any Lesion length including focal in stent restenosis or diffuse in stent restenosis The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic followup, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin Aspirin Both Clopidogrel and TIclopidine Sirolimus eluting stent Stainless steel and/or Contrast media (patients with documented sensitivity to contrast which can be effectively premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled) Systemic (intravenous) Everolimus use within 12 months. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study Noncardiac comorbid conditions are present with life expectancy &lt;1 year or that may result in protocol noncompliance (per site investigator's medical judgment) Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint followup period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>drug-coated Balloon</keyword>
	<keyword>recurrent In-Stent restenosis</keyword>
</DOC>